Janux Therapeutics Starts Phase 1b Studies with JANX007 in Prostate Cancer
May 5, 2025
Phase 1b expansion study initiated in taxane-naïve mCRPC patients Janux Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying
